In pre-clinical models employing two independently derived cell lines, proficient and deficient in Cpt1a, we observed that combining 7.16.4 mAb treatment and Cpt1a deletion significantly attenuated tumor growth and proliferation and elevated tumor cell apoptosis, compared to all other conditions (Fig. 7d–f, and Supplementary Fig. 12a). Here, CPT1A is linked to neoplasm.